[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"third-line-and-beyond-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:third-line-and-beyond-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100599490","phase-2-low-dose-trifluridinetipiracil-with-bevacizumab-in-mcrc-100599490",false,"NCT07085169","Low-dose Trifluridine\u002FTipiracil With Bevacizumab in mCRC","Low-dose Trifluridine\u002FTipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study","Inclusion Criteria:\n\n1. age over 60 years old, male and female\n2. histologically confirmed adenocarcinoma of the colon or rectum\n3. patients with metastatic or advanced unresectable diseases who had received two or more previous chemotherapy regimens or intolerance to last regimen\n4. with or without measurable lesions\n5. ECOG 0 to 2, expected survival time over 3 months\n6. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109\u002FL, White blood count ≥3.5x109\u002FL, Platelets ≥75x109\u002FL, Hemoglobin (Hb) ≥80g\u002FL, ALT\u002FAST ≤2.5x ULN (for patient with liver metastasis ALT\u002FAST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN.\n7. Signed informed consent and willing to follow the study protocol\n\nExclusion Criteria:\n\n1. symptomatic metastases of central nervous system\n2. other primary malignancies\n3. uncontrollable comorbidities, such as hypertension, thrombotic diseases, chronic kidney disease\n4. organ functions that cannot tolerate study treatment\n5. bowel obstruction or other conditions affecting oral administration\n6. allergic to study medication\n7. other conditions that patients are unsuitable for this study assessed by the investigators","ALL","60 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine\u002Ftipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine\u002Ftipiracil (17.5 mg\u002Fm2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg\u002Fkg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.",[26,27,28,29],"Colo-rectal Cancer","Third-line and Beyond Therapy","TAS 102","Bevacizumab","RECRUITING","2025-07-24",{"date":33,"type":34},"2025-07-25","ACTUAL",{"date":36,"type":20},"2025-08-01",{"date":38,"type":20},"2028-08-01",{"name":40,"class":41},"Ruijin Hospital","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100572098","phase-2-efficacy-and-safety-of-vorolanib-monotherapy-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung-cancer-patients-a-single-arm-prospective-open-label-phase-ii-clinical-study-100572098","NCT06728852","Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","Vigor","Inclusion Criteria:\n\n1. Sign the informed consent\n2. Pathologically or cytologically diagnosed with metastatic\u002Frelapsed advanced NSCLC, with measurable lesions (according to RECIST 1.1)\n3. Previously received at least two systemic therapies, allowing for third-line or higher chemotherapy or unable to tolerate chemotherapy\n4. Patients with negative results for driver gene testing or patients with positive results who have already received relevant targeted drugs or systemic anti-tumor treatments and are either resistant or unable to tolerate them\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. Expected survival time ≥ 3 months\n6. Normal major organ function: renal function with creatinine clearance rate ≥ 60 mL\u002Fmin; liver function with bilirubin ≤ 1.5× upper limit of normal (ULN), ALT\u002FAST ≤ 2.5× ULN (for patients with documented liver metastasis, AST and ALT levels ≤ 5× ULN)\n7. Good hematological function, defined as an absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL, platelet count ≥ 100×10\\^9\u002FL, hemoglobin ≥ 90g\u002FL (without blood transfusion or erythropoietin \\[EPO\\] dependency within the last 7 days)\n8. Good coagulation function, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN; if the subject is on anticoagulation therapy, PT should be within the intended therapeutic range of the anticoagulant\n9. Female patients of childbearing potential must agree to use contraception (e.g., intrauterine device, contraceptives, or condoms) during the study and for 6 months after the study ends; must not be breastfeeding and must have a negative serum or urine pregnancy test within 7 days before enrollment. Male patients must agree to use contraception during the study and for 6 months after the study ends\n10. Patients with well-controlled pleural or peritoneal effusions that do not cause grade 2 or higher respiratory syndrome (≥ CTCAE grade 2) can be included\n11. Patients without clinical symptoms of intracranial hypertension caused by brain metastases or with brain metastasis symptoms that are stable after prior treatment (radiation therapy or surgery) of brain or meningeal metastasis (usually requiring more than 4 weeks post-radiation therapy)\n\nExclusion Criteria:\n\n1. Previously failed treatment with multi-target anti-angiogenic drugs, such as anlotinib, cabozantinib, apatinib, lenvatinib, etc. The use of bevacizumab is allowed, but the last administration must be more than 3 weeks before enrollment\n2. Small cell lung cancer (including small cell carcinoma, non-small cell lung cancer mixed with other types of tumors)\n3. Testing positive for driver genes but not treated with TKIs\n4. Tumor invasion of large blood vessels, central squamous cell carcinoma of the lung with cavitation, or non-small cell lung cancer with hemoptysis (\\>5ml\u002Fday), or where the tumor is likely to invade important blood vessels and cause fatal bleeding during the subsequent study period\n5. Accompanied by other types of malignant tumors within the past 5 years or currently\n6. Planning to receive systemic anti-tumor therapy within 4 weeks before enrollment or during the study period, including cytotoxic therapy, signal transduction inhibitors, and immunotherapy (or mitomycin C within 6 weeks before receiving experimental drug therapy); received extended-field radiation therapy (EF-RT) within 4 weeks before enrollment or limited-field radiation therapy within 2 weeks before enrollment with evaluation of lesions recommended\n7. Unremitting toxic reactions caused by previous treatment, CTCAE grade \\>1, excluding hair loss\n8. Various factors affecting oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea, bowel obstruction)\n9. Pleural effusion or ascites leading to respiratory syndrome (≥CTCAE grade 2)\n10. Symptoms of brain metastasis not controlled and treated within 2 months\n11. Presence of any severe or uncontrolled disease\n12. Major surgery, open biopsy, or significant traumatic injury within 28 days before enrollment\n13. Bleeding diathesis or history of significant bleeding, regardless of severity; any wound, ulcer, or fracture that has not healed following a bleeding or bleeding event (≥CTCAE grade 3)\n14. Arterial\u002Fvenous thrombosis within 6 months, such as cerebrovascular accident (including transient ischemic attack), venous thrombosis, pulmonary embolism\n15. History of substance abuse that cannot be quit or diagnosed with psychiatric disorders\n16. Participated in other clinical trials of anti-tumor drugs within 4 weeks\n17. Diagnosed with diseases that severely jeopardize patient safety or affect the completion of this study\n18. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1\u002F2 antibody positive); untreated active hepatitis B; active HCV infection (HCV antibody positive and HCV-RNA levels above detection limit)","18 Years","70 Years",{"count":52,"type":20},32,[23],"This study evaluates the efficacy and safety of Vorolanib as monotherapy for advanced non-small cell lung cancer (NSCLC) patients receiving third-line or higher treatments. It is a single-center, single-arm, prospective Phase II clinical trial. Thirty-two patients who have undergone at least two lines of systemic therapy and exhibited progression or recurrence will receive 300 mg of Vorolanib daily until disease progression, intolerable toxicity, withdrawal of consent, or death. The primary endpoint is the 6-month progression-free survival (PFS) rate. Secondary endpoints include PFS, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. This research aims to expand the clinical applications of Vorolanib in NSCLC, providing a basis for further investigation.",[56,57,27,58],"Advanced Non-small Cell Lung Cancer (NSCLC)","Recurrent or Metastatic Lung Cancer","Angiogenesis Inhibition in Oncology","2024-12-08",{"date":61,"type":34},"2024-12-11",{"date":63,"type":20},"2024-12-01",{"date":65,"type":20},"2026-12-01",{"name":67,"class":41},"Li-kun Chen",1]